DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160758

To compare the efficacy of alternate day versus everyday dosing of atorvastatin in hyperlipidemic rabbits

Sarita Mulkalwar, Pravin Golande

Abstract


Background: Muscle pain is often seen with statin therapy. Statins have also been associated with increase in liver transaminases as they lead to hepatic injury. The half - life of atorvastatin is increased due to its active metabolites which suggest the possibility for its alternate day use over everyday use. This would mean reduction in side effects such as hepatotoxicity and myopathy and solving the problem of statin underutilization in patients of lower socio economic class.

Methods: Institutional Animal Ethics Committee (IAEC) approval was taken before the start of study. Hyperlipidemia was induced in New Zealand White rabbits by oral administration of high fat diet for 3 weeks. After 3 weeks all the laboratory tests were done to see if animals had developed hyperlipidemia. This day was considered as day 0 for further study. Hyperlipidemic rabbits were divided into two groups, first group receiving atorvastatin orally (5mg/kg) daily for duration of 6 weeks while the other group receiving atorvastatin orally (5mg/kg) at alternate days for same duration. All the laboratory tests were done at week 3 and week 6. Both the treatment groups were compared pairwise and also with day 0 to check for efficacy and safety.

Results: At the end of 6 weeks every day and alternate day dosing of atorvastatin, showed a statistical decrease in total cholesterol, triglycerides and LDL-C with respect to day 0. Pairwise comparison did not show any statistical difference in between the two treatment groups. Statistical increase in HDL-C was seen only with everyday dosing of atorvastatin as compared to day 0. Pairwise comparison showed statistical difference in between two treatment groups.

At the end of 6 weeks, there was no statistical difference in SGOT, SGPT and CK levels when compared to day 0.

Conclusions: Alternate day dosing of atorvastatin was as efficacious and safe as everyday dosing of atorvastatin in hyperlipidemic New Zealand White rabbits, thus being a cost effective alternative.


Keywords


Atorvastatin, Hyperlipidemia, Rabbits

Full Text:

PDF

References


Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol lowering treatment: prospective meta - analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267-78.

Statin Therapy: Risks vs Benefit: An Expert Interview With Eliot A. Brinton, MD. 2015 [cited 2015 May 8] Available from www.medscape.org/viewarticle/481357

Brunton LL, Chabner BA, Knollmann BC. In, Goodman & Gilman’s. The Pharmacological Basis of Therapeutics. 12th edition. California. The Mc Graw-Hill Companies, Inc. Drug therapy for hypercholesterolemia and dyslipidemia. 2011:896.

Suzuki M, Kakuta H, Takahashi A, Shimano H, Tada-lida k et al. Effects of Atorvastatin on glucose metabolism and insulin resistane in KK/Ay mice. J Atherosclerosis Thrombosis. 2004;12(2):77-84.

Purohit A, Joshi K, Kotru B, Kotru S, Ram H. Histological study of antiatherosclerotic effect of Propolis in induced hypercholestrolemic male albino Rabbits. Indian J Life sciences. 2012;2(2):384-90.

Pramanik S, Das AK, Chakrabarty M, Bandopadhyay SK, Ghosh M, Dalai CK. Efficacy of alternate-day versus everyday dosing of atorvastatin. Indian J Pharmacol. 2012;44(3):362-5.

Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of Atorvastatin. J Cardiovasc Pharmacol Ther. 2003;8(2):123-26.

Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of Atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J. 2002;144(4):674-77.

Aghosadeghi K, Zare D. Efficacy of alternate day dosing of Atorvastatin. Journal of Chinese Clinical Medicine. 2007;2(10):163-6.

Piamsomboon C, Laothavorn P, Saguonwong S, Chatloong B, Nasawadi C, Tanprasert P. Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai. 2002;85(3):297-300.

Barter P. HDL Cholesterol, very low levels of LDL Cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-10.

Ridker PM. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333-9.

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence of statin therapy in elderly patients. JAMA. 2002;288:455-61.

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.

Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol lowering therapy. Am J Manag Care. 2006;12:21-8.